Xilio Therapeutics, Inc. (XLO)
8.94
+0.03
(+0.34%)
USD |
NASDAQ |
Sep 09, 15:06
Xilio Therapeutics Shareholders Equity (Quarterly) : 72.26M for June 30, 2026
Shareholders Equity (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Shareholders Equity (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 72.26M |
| March 31, 2026 | 72.54M |
| December 31, 2025 | 35.27M |
| September 30, 2025 | -8.095M |
| June 30, 2025 | 7.069M |
| March 31, 2025 | 10.70M |
| December 31, 2024 | 17.60M |
| September 30, 2024 | 20.97M |
| June 30, 2024 | 33.42M |
| March 31, 2024 | 25.76M |
| December 31, 2023 | 36.83M |
| September 30, 2023 | 52.50M |
| Date | Value |
|---|---|
| June 30, 2023 | 67.38M |
| March 31, 2023 | 84.79M |
| December 31, 2022 | 105.65M |
| September 30, 2022 | 126.30M |
| June 30, 2022 | 144.22M |
| March 31, 2022 | 166.12M |
| December 31, 2021 | 185.43M |
| September 30, 2021 | 86.43M |
| June 30, 2021 | 101.58M |
| March 31, 2021 | 123.75M |
| December 31, 2020 | -5.285M |
Shareholders' Equity Definition
Represents the value of Shareholders' Equity as of the close of the report date, belonging to both Preferred and Common Equity Shareholders.
Shareholders Equity (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Shareholders Equity (Quarterly) Benchmarks
| Cue Biopharma, Inc. | 2.31M |
| ACADIA Pharmaceuticals, Inc. | 1.307B |
| Alnylam Pharmaceuticals, Inc. | 1.354B |
| Anika Therapeutics, Inc. | 137.28M |
| Savara, Inc. | 143.66M |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 154.25M |
| Total Liabilities (Quarterly) | 81.99M |
| Debt to Equity Ratio | 0.0872 |
| Current Ratio | 4.254 |
| Net Debt Paydown Yield | 0.50% |